StockNews.AI
IONS
StockNews.AI
181 days

Ionis reports fourth quarter and full year 2024 financial results

1. Ionis launched TRYNGOLZA, marking its transition to a commercial-stage biotech. 2. Three additional medicines expected in the next three years to boost growth.

2m saved
Insight
Article

FAQ

Why Bullish?

The launch of TRYNGOLZA signifies strategic growth and market expansion, similar to past drug approvals leading to stock surges.

How important is it?

The launch of a new drug coupled with future prospects directly affects Ionis's revenue potential and stock valuation.

Why Long Term?

The expected launches over three years indicate sustained growth potential, akin to Ionis's previous successful product launches.

Related Companies

IONS
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024. “With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Over the next three years, we expect three more.

Related News